Concepedia

Publication | Open Access

Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?

DOIFull Paper Access

14

Citations

13

References

2023

Year

Karin Černá, Dana Ďuricová, Martin Lukás, Martin Kolář, Naděžda Machková, Veronika Hrubá, Katarína Mitrová, Kristýna Kubíčková, Marta Kostrejová, Jakub Jirsa,
Crohn s & Colitis 360

Abstract

Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.

References

YearCitations

Page 1